Biotron Share Price Up, Letter to Shareholders Includes Useful Information

By ,

Early this morning, the share price of Biotron Limited [ASX:BIT] managed to spike up 7.69%, trading at 14 cents per share. At time of writing, shares are currently close to yesterday’s market closing price at 13.5 cents each.

The stock has been trading sideways since 29 November:

Biotron Share Price


In a letter to the shareholders, the company disclosed a couple of useful pieces of information.

Interested in bio-tech stocks, but don’t know where to start? We’ve got a free report available here, that guides you through making the best picks.

Presentation of data

The letter to shareholders summarised the progress the company has made over the course of the year.

This includes the successful phase 2 trial, which showed that the company’s BIT225 drug attacks HIV-1 in macrophage cells.

Perhaps most notable in the letter to shareholders was news the company has presented data from the Phase 2 trial to the scientific community.

This took place at the HIV DART and Emerging Viruses 2018 conference in Miami, Florida. Biotron’s head of Research and Development, Dr Carolyn Luscombe, was presented with the 2018 HIV DART Poster Award.

Commercialisation meetings over several months, shift to Hepatitis B virus

This is important for the company’s long-term future as the path to commercialisation begins with sharing the results of trials with fellow scientists.

The company also provided a timeline for future meetings with potential partners, saying that there would be ‘multiple meetings, spread several months’.

Finally, the company flagged that it would be evaluating the activity of other Biotron compounds against the Hepatitis B virus, marking a significant step towards diversification of its drug portfolio.

So, while it remains a speculative play, this news taken as a whole could be interpreted to mean that investors will have to wait months before significant news moves its share price.


Lachlann Tierney,
For Money Morning

PS: Bio-tech stocks frequently net massive gains. Learn how to pick the best bio-tech stocks with our free report. The download is available right here.

About Lachlann Tierney

Lachlann Tierney is an Analyst for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest…

Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021…

Three Stocks to Watch during the Coronavirus Rollercoaster

Market volatility is continuing to rise amidst the ongoing global pandemic. Worst yet, it is difficult to pinpoint when this is likely to end. Markets are up one day and crashing down the next. It is a telling sign when investors begin to look for safety among some of Australia’s most speculative small-caps…

A Look at the Orthocell Share Price: Can It Keep Going Up? 

Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward. 

Biotron Share Price Volatile as Investors Digest Latest Release

It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing. Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors. The Biotron share price is down from a high of … Read More

Biotron Share Price Up as it Responds to ASX Query

The share price of Biotron is up 9.5% and trading at $0.115, at time of writing. It has been an exciting time for Biotron shareholders who, last month, could have sold their shares for a whopping $0.445.

Huge Gains for Biotron Share Price After Promising HIV Drug Trial Results

In just the past three trading days Biotron Limited [ASX:BIT] has rocketed up. As at time of writing, it’s trading at $.093, a 489% increase from three trading days ago where it closed at $.019. Biotron is a biotechnology research company working on a range of antiretroviral drugs. Antiretroviral drugs fight viruses, and Biotron has … Read More